Propranolol for the treatment of vascular sarcomas

Michael J. Wagner*, Lee D. Cranmer, Elizabeth T. Loggers, Seth M. Pollack

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

31 Scopus citations


Vascular sarcomas are abnormal proliferations of endothelial cells. They range from benign hemangioma to aggressive angiosarcoma, and are characterized by dysregulated angiogenic signaling. Propranolol is a β-adrenergic receptor inhibitor that has demonstrated clinical efficacy in benign infantile hemangioma, and is now being used experimentally for more aggressive vascular sarcomas and other cancers. In this review, we discuss the use of propranolol in targeting these receptors in vascular tumors and other cancers.

Original languageEnglish (US)
Pages (from-to)51-58
Number of pages8
JournalJournal of Experimental Pharmacology
StatePublished - 2018
Externally publishedYes


  • Angiosarcoma
  • Cancer
  • Propranolol
  • Vascular sarcoma
  • β-blocker

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'Propranolol for the treatment of vascular sarcomas'. Together they form a unique fingerprint.

Cite this